NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment

CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.

Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
Credit: Creative Medical Technology Holdings
Already have an account? Sign in.
08/20/2026 · 3:21 PM
CELZ
/ Read more

Feed↓

Cerebras Boosts 2026 Forecast Amid OpenAI and Hyperscaler Deals
11/12/2026 · 4:36 PM

Cerebras Boosts 2026 Forecast Amid OpenAI and Hyperscaler Deals

Cerebras expects $940–960M in 2026 revenue as it expands capacity to support a $20B OpenAI contract and new hyperscaler agreements.

/ Subscriber only
Cisco Beats Estimates, Lifts Full-Year Outlook and AI Revenue Target to $9B
Featured/ 11/12/2026 · 4:21 PM

Cisco Beats Estimates, Lifts Full-Year Outlook and AI Revenue Target to $9B

Cisco shares rose after beating estimates with record revenue and raising its AI hyperscaler target to $9B while lifting full-year guidance.

/ Subscriber only
SpaceX and Tesla Merger Talks Advance Toward Possible December Announcement
Featured/ 11/12/2026 · 3:34 PM

SpaceX and Tesla Merger Talks Advance Toward Possible December Announcement

Special committees of independent directors are reviewing a possible SpaceX-Tesla combination valued around $3.5 trillion.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI